Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

NCT06161844 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of semaglutide injection (HD1916) on blood sugar control in adults with type 2 diabetes over 32 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 506 people

Who can join Ages 18–75 · all sexes

Timeline Started 2024-02 · est. completion 2025-05

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06161844 ↗

Description as written by the study sponsor.

To evaluate the similarity of the efficacy and safety of semaglutide injection (HD1916) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.

Treatments tested

semaglutide injection (HD1916) Drug

Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: HD1916
Ozempic® Drug

Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: Ozempic Injectable Product

Main thing measured	Change from baseline to week 32 in glycosylated haemoglobin (HbA1c)
Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06161844 ↗